2-[4-(Propan-2-yl)cyclohexyl]propan-2-ol | 62435-07-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-[4-(Propan-2-yl)cyclohexyl]propan-2-ol
• 英文别名: 2-(4-propan-2-ylcyclohexyl)propan-2-ol
• CAS: 62435-07-8
• 化学式: C₁₂H₂₄O
• 分子量: 184.32
• InChiKey: YVJDFHXFDFYOME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150274696A1

  公开（公告）日：2015-10-01

  Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R 2 is a bicyclic heterocycle, and R 1 , R 3 , R 4 , R 5 and R 6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.

  具有以下式(I)或其立体异构体或药物可接受的盐的化合物，其中R2是双环杂环，R1、R3、R4、R5和R6如此定义，可用作激酶调节剂，包括IRAK-4调节剂。
• HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150284382A1

  公开（公告）日：2015-10-08

  Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R 2 is a monocyclic heteroaryl group, and R 1 , R 3 , R 4 , R 5 and R 6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

  具有以下式(I)或其立体异构体或药学上可接受的盐的化合物，其中R2是单环杂环基团，而R1、R3、R4、R5和R6如所定义的，可用作激酶调节剂，包括IRAK-4抑制剂。
• 5-SUBSTITUTED BENZIMIDAZOLE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE BOTH HAVING AMPK ACTIVATION EFFECT
  申请人：Shionogi & Co., Ltd

  公开号：EP3459949A1

  公开（公告）日：2019-03-27

  Provided is a compound which is useful as an AMPK activator. A compound represented by formula: wherein R1 is hydrogen, or substituted or unsubstituted alkyl; R2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocyclyl; T is -CR5= or -N=; X is a single bond, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocyclyl; Y is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocyclyl; Z is RSRS'(O=)S=N-, RSRS'(O=)S=N-R2f-, RSRS'(O=)S=N-C(=O)-, (RN)N=S(=O)(RS)-, (RN)N=S(=O)(RS)-R2f-, RSRS'(RN'-N=)S=N-, or the like; n is an integer 1 or 2; RS and RS' are each independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or the like; R2f is substituted or unsubstituted alkylene; RN is each independently hydrogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, or the like; RN' is hydrogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl or the like; and R3, R4 and R5 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, or the like, or its pharmaceutically acceptable salt.

  本文提供了一种可用作 AMPK 激活剂的化合物。一种由式表示的化合物： 其中 R1 是氢，或取代或未取代的烷基； R2是取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的芳基、取代或未取代的杂芳基、取代或未取代的环烷基、取代或未取代的环烯基、取代或未取代的杂环基； T 是-CR5= 或-N=； X 是单键、取代或未取代的芳基、取代或未取代的杂芳基、取代或未取代的环烷基、取代或未取代的环烯基或取代或未取代的杂环基； Y 是取代或未取代的芳基、取代或未取代的杂芳基、取代或未取代的环烷基、取代或未取代的环烯基、或取代或未取代的杂环基； Z 是 RSRS'(O=)S=N-、RSRS'(O=)S=N-R2f-、RSRS'(O=)S=N-C(=O)-、(RN)N=S(=O)(RS)-、 (RN)N=S(=O)(RS)-R2f-，RSRS'(RN'-N=)S=N-，或类似成分； n 是整数 1 或 2； RS 和 RS'各自独立地是取代或未取代的烷基、取代或未取代的环烷基、取代或未取代的杂环烷基或类似物； R2f 是取代或未取代的亚烷基； RN 各独立地为氢、氰基、取代或未取代的烷基、取代或未取代的烷羰基或类似物； RN' 是氢、氰基、取代或未取代的烷基、取代或未取代的烷羰基、取代或未取代的烷氧羰基或类似物；以及 R3、R4 和 R5 各自独立地为氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的芳基、取代或未取代的杂芳基、取代或未取代的环烷基、取代或未取代的环烯基、取代或未取代的杂环基或类似物，或其药学上可接受的盐。
• Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
  申请人：Bellenie Benjamin Richard

  公开号：US10004732B2

  公开（公告）日：2018-06-26

  The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

  本发明提供了抑制 PI 3-kinase gamma 异构体活性的式 (I) 化合物，可用于治疗由 PI 3-kinase gamma 异构体活化介导的疾病。
• Heteroaryl substituted pyridyl compounds useful as kinase modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10023562B2

  公开（公告）日：2018-07-17

  Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

  具有下式的化合物 或其立体异构体或药学上可接受的盐，其中 R2 是单环杂芳基，R1、R3、R4、R5 和 R6 如本文所定义，可用作激酶调节剂，包括 IRAK-4 抑制剂。